Product Description for VEGFR-3 / Flt-4
Properties for VEGFR-3 / Flt-4
|Synonyms||FLT4, Tyrosine-protein kinase receptor FLT4, VEGF Receptor 3, VEGFR3, Vascular endothelial growth factor receptor 3|
|Molecular weight||120 kDa|
|PDF datasheet||View Datasheet|
|Manufacturer||Acris Antibodies GmbH|
|Purity||> 90 %|
|Add. information||Centrifuge vials before opening!|
|Background||Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.|
|Storage||Prior to and following reconstitution store the antibody at -20°C.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.